The “On the Wings of Super HAEro – 5 Years of Joint Success” organized by Takeda was held on Wednesday, May 21, at the Hilton Hotel in Belgrade. The occasion for the gathering was the fifth anniversary of the paradigm shift in the treatment of hereditary angioedema (HAE) in the Republic of Serbia.
This important anniversary brought together numerous healthcare professionals, representatives of patient associations, members of the Takeda team, as well as representatives of our team who have been working on the development of a digital solution for the purpose of ensuring better monitoring patients diagnosed with this rare disease.
Hereditary angioedema (HAE) is a rare disease that manifests itself as sudden swelling in different parts of the body, often with serious consequences for the health and life quality of patients. It is estimated that there are currently about 100 people living in Serbia with this diagnosis. That is why any progress in treatment and support for patients is of utmost importance.
During a rich agenda, the participants discussed the most important topics that accompanied the lives of patients with HAE – from the challenges in diagnosis, changes in the treatment paradigm and experiences in the treatment of first adult and paediatric patients, to the importance of regular evaluation and plans for the future. Special attention was paid to multidisciplinary cooperation, with a review of the changes to the HAE treatment guide.
The head of our development team, Filip Maljković, presented the development of the Digital Clinical HAE REgister Pilot (D-E-E-P), a solution that aims to enable doctors to regularly monitor the course of the disease and the life quality of patients, as well as better control of the disease itself. Digital platforms such as the aforementioned solution provide a major contribution to everyday clinical practice, while the integration of data into the Heliant health information system ensures the creation of sustainable support systems for patients, doctors and the entire healthcare system. It is the integration of innovative technological solutions that is key to further progress in the treatment of rare diseases.
The event was an opportunity to gather all relevant stakeholders in one place in order to exchange experiences and further improve the care of patients diagnosed with HAE.